• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics.基于 13C-稳定同位素示踪剂的代谢组学研究:葡萄糖激酶激活剂对肝脏中间代谢的影响。
Biochem J. 2012 Jun 15;444(3):537-51. doi: 10.1042/BJ20120163.
2
Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.用 exendin-4 治疗可改善葡萄糖激酶激活剂治疗的 db/db 小鼠的抗糖尿病疗效并逆转肝脂肪变性。
Eur J Pharmacol. 2013 Aug 15;714(1-3):188-92. doi: 10.1016/j.ejphar.2013.06.015. Epub 2013 Jun 25.
3
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.小分子葡萄糖激酶激活剂扰乱脂代谢平衡并在啮齿类动物中诱导脂肪肝:对人类治疗应用的警告。
Br J Pharmacol. 2013 Jan;168(2):339-53. doi: 10.1111/j.1476-5381.2012.02184.x.
4
Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.葡萄糖激酶激活剂PSN-GK1表现出增强的降血糖和促胰岛素分泌作用。
Diabetologia. 2007 Jun;50(6):1277-87. doi: 10.1007/s00125-007-0646-8. Epub 2007 Apr 6.
5
Hepatic glycogen cycling contributes to glucose lowering effects of the glucokinase activator LCZ960.肝糖原循环有助于葡萄糖激酶激活剂 LCZ960 的降血糖作用。
Eur J Pharmacol. 2013 Sep 5;715(1-3):89-95. doi: 10.1016/j.ejphar.2013.06.014. Epub 2013 Jun 28.
6
Glycogenesis from glucose and ureagenesis in isolated perfused rat livers. Influence of ammonium ion, norvaline, and ethoxyzolamide.分离灌注大鼠肝脏中由葡萄糖生成糖原及尿素生成的过程。铵离子、正缬氨酸和乙氧唑胺的影响。
J Biol Chem. 1994 Mar 18;269(11):7879-86.
7
Isotopomer studies of gluconeogenesis and the Krebs cycle with 13C-labeled lactate.利用13C标记的乳酸对糖异生作用和三羧酸循环进行的同位素异构体研究。
J Biol Chem. 1993 Dec 5;268(34):25509-21.
8
Treatment with glucokinase activator, YH-GKA, increases cell proliferation and decreases glucotoxic apoptosis in INS-1 cells.使用葡萄糖激酶激活剂YH-GKA进行治疗可增加INS-1细胞的增殖并减少糖毒性诱导的细胞凋亡。
Eur J Pharm Sci. 2014 Jan 23;51:137-45. doi: 10.1016/j.ejps.2013.09.005. Epub 2013 Sep 18.
9
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.葡萄糖激酶激活剂和二甲双胍对肝细胞葡萄糖调控基因表达的相反作用。
Diabetes Obes Metab. 2017 Aug;19(8):1078-1087. doi: 10.1111/dom.12910. Epub 2017 Apr 10.
10
Modulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysis.葡萄糖、小分子激活剂和葡萄糖激酶调节蛋白对葡萄糖激酶的调节:稳态动力学和基于细胞的分析。
Biochem J. 2012 Feb 1;441(3):881-7. doi: 10.1042/BJ20110721.

引用本文的文献

1
G6PC2 controls glucagon secretion by defining the set point for glucose in pancreatic α cells.G6PC2 通过确定胰腺α细胞中葡萄糖的设定点来控制胰高血糖素的分泌。
Sci Transl Med. 2025 Jan;17(779):eadi6148. doi: 10.1126/scitranslmed.adi6148. Epub 2025 Jan 1.
2
Current Insight on the Role of Glucokinase and Glucokinase Regulatory Protein in Diabetes.当前对葡萄糖激酶和葡萄糖激酶调节蛋白在糖尿病中作用的认识。
Mini Rev Med Chem. 2024;24(7):674-688. doi: 10.2174/1389557523666230823151927.
3
From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria.从非酒精性脂肪肝到肝细胞癌:线粒体(失)适应的故事
Biology (Basel). 2023 Apr 14;12(4):595. doi: 10.3390/biology12040595.
4
Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.多扎格列艾汀治疗2型糖尿病的疗效与安全性:一项Meta分析和试验序贯分析
Front Cardiovasc Med. 2022 Nov 23;9:1041044. doi: 10.3389/fcvm.2022.1041044. eCollection 2022.
5
Transcriptome and metabolome after porcine hemodynamic-directed CPR compared with standard CPR and sham controls.与标准心肺复苏和假手术对照组相比,猪血流动力学导向心肺复苏后的转录组和代谢组。
Resusc Plus. 2022 May 11;10:100243. doi: 10.1016/j.resplu.2022.100243. eCollection 2022 Jun.
6
Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator.肝葡萄糖代谢紊乱与葡萄糖激酶激活剂长期治疗后疗效降低有关。
PLoS One. 2022 Mar 21;17(3):e0265761. doi: 10.1371/journal.pone.0265761. eCollection 2022.
7
Maintaining Effective Beta Cell Function in the Face of Metabolic Syndrome-Associated Glucolipotoxicity-Nutraceutical Options.面对代谢综合征相关糖脂毒性时维持有效的β细胞功能——营养保健品选择
Healthcare (Basel). 2021 Dec 21;10(1):3. doi: 10.3390/healthcare10010003.
8
Dimethyl Fumarate, an Approved Multiple Sclerosis Treatment, Reduces Brain Oxidative Stress in SIV-Infected Rhesus Macaques: Potential Therapeutic Repurposing for HIV Neuroprotection.富马酸二甲酯,一种已获批准的多发性硬化症治疗药物,可降低感染猴免疫缺陷病毒的恒河猴大脑中的氧化应激:对HIV神经保护的潜在治疗用途拓展。
Antioxidants (Basel). 2021 Mar 9;10(3):416. doi: 10.3390/antiox10030416.
9
Malic Enzyme Couples Mitochondria with Aerobic Glycolysis in Osteoblasts.苹果酸酶将成骨细胞中的线粒体与有氧糖酵解偶联。
Cell Rep. 2020 Sep 8;32(10):108108. doi: 10.1016/j.celrep.2020.108108.
10
Collapse of the hepatic gene regulatory network in the absence of FoxA factors.FoxA 因子缺失时肝基因调控网络的崩溃。
Genes Dev. 2020 Aug 1;34(15-16):1039-1050. doi: 10.1101/gad.337691.120. Epub 2020 Jun 19.

本文引用的文献

1
Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function.长期使用小分子葡萄糖激酶激活剂对葡萄糖代谢、血脂谱和肝功能的影响。
J Diabetes Investig. 2011 Aug 2;2(4):276-9. doi: 10.1111/j.2040-1124.2011.00104.x.
2
Down-regulation of hepatic urea synthesis by oxypurines: xanthine and uric acid inhibit N-acetylglutamate synthase.黄嘌呤和尿酸通过下调肝尿素合成:抑制 N-乙酰谷氨酸合成酶。
J Biol Chem. 2011 Jun 24;286(25):22055-68. doi: 10.1074/jbc.M110.209023. Epub 2011 May 3.
3
Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism.携带 GCKR Pro446Leu 多态性的个体对强化生活方式干预的甘油三酯反应增强。
J Clin Endocrinol Metab. 2011 Jul;96(7):E1142-7. doi: 10.1210/jc.2010-2324. Epub 2011 Apr 27.
4
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.吡格列酮(RO4389620),一种新型葡萄糖激酶激活剂,可降低 2 型糖尿病患者空腹和葡萄糖负荷后的血浆葡萄糖:一项机制研究。
J Clin Endocrinol Metab. 2010 Nov;95(11):5028-36. doi: 10.1210/jc.2010-1041. Epub 2010 Aug 25.
5
Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study.葡萄糖激酶激活酶 GCKR 多态性会增加甘油三酯和游离脂肪酸的血浆水平,但不会增加路德维希港风险和心血管健康研究中的心血管风险。
Horm Metab Res. 2010 Jun;42(7):502-6. doi: 10.1055/s-0030-1249637. Epub 2010 Mar 29.
6
Recent advances in glucokinase activators for the treatment of type 2 diabetes.用于治疗2型糖尿病的葡萄糖激酶激活剂的最新进展。
Drug Discov Today. 2009 Aug;14(15-16):784-92. doi: 10.1016/j.drudis.2009.05.013. Epub 2009 Jun 9.
7
Assessing the potential of glucokinase activators in diabetes therapy.评估葡萄糖激酶激活剂在糖尿病治疗中的潜力。
Nat Rev Drug Discov. 2009 May;8(5):399-416. doi: 10.1038/nrd2850. Epub 2009 Apr 17.
8
Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks.针对2型糖尿病中的肝脏葡萄糖激酶:权衡利弊
Diabetes. 2009 Jan;58(1):18-20. doi: 10.2337/db08-1470.
9
Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass.小分子葡萄糖激酶激活剂对葡萄糖代谢及β细胞量的影响
Endocrinology. 2009 Mar;150(3):1147-54. doi: 10.1210/en.2008-1183. Epub 2008 Nov 13.
10
Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats.恢复肝葡萄糖激酶表达可纠正Zucker糖尿病脂肪大鼠的肝脏葡萄糖通量并使血糖正常化。
Diabetes. 2009 Jan;58(1):78-86. doi: 10.2337/db08-1119. Epub 2008 Oct 24.

基于 13C-稳定同位素示踪剂的代谢组学研究:葡萄糖激酶激活剂对肝脏中间代谢的影响。

Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics.

机构信息

Division of Child Development and Metabolic Disease, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

出版信息

Biochem J. 2012 Jun 15;444(3):537-51. doi: 10.1042/BJ20120163.

DOI:10.1042/BJ20120163
PMID:22448977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3679927/
Abstract

GKAs (glucokinase activators) are promising agents for the therapy of Type 2 diabetes, but little is known about their effects on hepatic intermediary metabolism. We monitored the fate of (13)C-labelled glucose in both a liver perfusion system and isolated hepatocytes. MS and NMR spectroscopy were deployed to measure isotopic enrichment. The results demonstrate that the stimulation of glycolysis by GKA led to numerous changes in hepatic metabolism: (i) augmented flux through the TCA (tricarboxylic acid) cycle, as evidenced by greater incorporation of (13)C into the cycle (anaplerosis) and increased generation of (13)C isotopomers of citrate, glutamate and aspartate (cataplerosis); (ii) lowering of hepatic [Pi] and elevated [ATP], denoting greater phosphorylation potential and energy state; (iii) stimulation of glycogen synthesis from glucose, but inhibition of glycogen synthesis from 3-carbon precursors; (iv) increased synthesis of N-acetylglutamate and consequently augmented ureagenesis; (v) increased synthesis of glutamine, alanine, serine and glycine; and (vi) increased production and outflow of lactate. The present study provides a deeper insight into the hepatic actions of GKAs and uncovers the potential benefits and risks of GKA for treatment of diabetes. GKA improved hepatic bioenergetics, ureagenesis and glycogenesis, but decreased gluconeogenesis with a potential risk of lactic acidosis and fatty liver.

摘要

GKAs(葡萄糖激酶激活剂)是治疗 2 型糖尿病的有前途的药物,但人们对它们对肝脏中间代谢的影响知之甚少。我们在肝脏灌注系统和分离的肝细胞中监测了(13)C 标记葡萄糖的命运。MS 和 NMR 光谱用于测量同位素丰度。结果表明,GKA 刺激糖酵解导致肝脏代谢发生许多变化:(i)通过 TCA(三羧酸)循环的通量增加,这表现在更多的(13)C 掺入循环(氨甲酰磷酸)和增加生成(13)C 异头物柠檬酸、谷氨酸和天冬氨酸(脱羧);(ii)降低肝脏[Pi]和升高[ATP],表示更高的磷酸化潜力和能量状态;(iii)刺激葡萄糖合成糖原,但抑制 3-碳前体合成糖原;(iv)增加 N-乙酰谷氨酸的合成,从而增强尿素生成;(v)增加谷氨酰胺、丙氨酸、丝氨酸和甘氨酸的合成;和(vi)增加乳酸的产生和流出。本研究深入了解了 GKA 在肝脏中的作用,并揭示了 GKA 治疗糖尿病的潜在益处和风险。GKA 改善了肝脏的生物能量学、尿素生成和糖异生,但降低了糖异生,可能导致乳酸酸中毒和脂肪肝。